The Italian ICD-11 field trial: clinical utility of diagnostic guidelines for schizophrenia and related disorders.
Clinical utility
Diagnosis
Goodness of fit
ICD-11
Schizoaffective disorder
Schizophrenia
Journal
International journal of mental health systems
ISSN: 1752-4458
Titre abrégé: Int J Ment Health Syst
Pays: England
ID NLM: 101294224
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
07
2019
accepted:
13
01
2020
entrez:
31
1
2020
pubmed:
31
1
2020
medline:
31
1
2020
Statut:
epublish
Résumé
The 11th revision of the International Classification of Diseases and Related Disorders (ICD-11) has been released. In order to test the clinical consistency and the clinical utility of the proposed guidelines the World Health Organization (WHO) has carried out the Ecological Implementation Field Studies in various countries. In this paper the results of the Italian field trials on the clinical utility of the ICD-11 diagnostic guideline concerning schizophrenia and related disorders will be presented. In Italy, field trials have been carried out at the Department of Psychiatry of the University of Campania "L. Vanvitelli". All patients showing any psychotic symptom and referring to the outpatient and inpatient units have been recruited. Patients were interviewed by two clinicians with whom they had not had any prior clinical contact. At the end of each interview, clinicians were asked to complete 12 questions about the clinical utility of the diagnostic guidelines as applied to each patient. Fourteen clinicians and 100 patients have been involved. The ICD-11 clinical guidelines were perceived as easy to use, with an adequate goodness of fit, clear and understandable and with an adequate level of details and specificity to describe the essential features of the diagnoses. Clinicians rated very positively their usefulness in describing the threshold between patient's disorder and normality. Despite still very positive, the guidelines have been perceived as less useful to select a treatment, to assess patients' prognosis and to communicate with other mental health professionals. The 11th revision of the chapter on Mental, Behavioural and Neurodevelopmental Disorders has made substantive changes to the conceptualization of mental disorders which could have impacted on their reliability and clinical utility. Results of the Italian field studies, in line with those reported by the international sample, highlight that ICD-11 has been rated as highly clinically useful by participating clinician, more than the ICD-10. This could be considered a good reason to be optimistic about the implementation of the ICD-11 among global clinicians.
Sections du résumé
BACKGROUND
BACKGROUND
The 11th revision of the International Classification of Diseases and Related Disorders (ICD-11) has been released. In order to test the clinical consistency and the clinical utility of the proposed guidelines the World Health Organization (WHO) has carried out the Ecological Implementation Field Studies in various countries. In this paper the results of the Italian field trials on the clinical utility of the ICD-11 diagnostic guideline concerning schizophrenia and related disorders will be presented.
METHODS
METHODS
In Italy, field trials have been carried out at the Department of Psychiatry of the University of Campania "L. Vanvitelli". All patients showing any psychotic symptom and referring to the outpatient and inpatient units have been recruited. Patients were interviewed by two clinicians with whom they had not had any prior clinical contact. At the end of each interview, clinicians were asked to complete 12 questions about the clinical utility of the diagnostic guidelines as applied to each patient.
RESULTS
RESULTS
Fourteen clinicians and 100 patients have been involved. The ICD-11 clinical guidelines were perceived as easy to use, with an adequate goodness of fit, clear and understandable and with an adequate level of details and specificity to describe the essential features of the diagnoses. Clinicians rated very positively their usefulness in describing the threshold between patient's disorder and normality. Despite still very positive, the guidelines have been perceived as less useful to select a treatment, to assess patients' prognosis and to communicate with other mental health professionals.
CONCLUSIONS
CONCLUSIONS
The 11th revision of the chapter on Mental, Behavioural and Neurodevelopmental Disorders has made substantive changes to the conceptualization of mental disorders which could have impacted on their reliability and clinical utility. Results of the Italian field studies, in line with those reported by the international sample, highlight that ICD-11 has been rated as highly clinically useful by participating clinician, more than the ICD-10. This could be considered a good reason to be optimistic about the implementation of the ICD-11 among global clinicians.
Identifiants
pubmed: 31998405
doi: 10.1186/s13033-020-0338-z
pii: 338
pmc: PMC6979076
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Abnorm Psychol. 2003 Aug;112(3):437-47
pubmed: 12943022
J Clin Psychol. 2013 Dec;69(12):1191-212
pubmed: 24122386
World Psychiatry. 2018 Jun;17(2):227-229
pubmed: 29856549
World Psychiatry. 2018 Oct;17(3):304-305
pubmed: 30192107
World Psychiatry. 2019 Feb;18(1):115-116
pubmed: 30600609
World Psychiatry. 2018 Oct;17(3):306-315
pubmed: 30192090
Schizophr Bull. 2007 Jan;33(1):108-12
pubmed: 17158191
World Psychiatry. 2015 Feb;14(1):82-90
pubmed: 25655162
Annu Rev Clin Psychol. 2016;12:133-55
pubmed: 26666967
Schizophr Bull. 2012 Sep;38(5):895-8
pubmed: 22987845
World Psychiatry. 2019 Feb;18(1):88-96
pubmed: 30600612
World Psychiatry. 2018 Oct;17(3):301-302
pubmed: 30192092
World Psychiatry. 2018 Jun;17(2):121-122
pubmed: 29856539
Epidemiol Psychiatr Sci. 2015 Jun;24(3):197-202
pubmed: 25204198
Riv Psichiatr. 2016 May-Jun;51(3):116-21
pubmed: 27362823
World Psychiatry. 2019 Jun;18(2):233-235
pubmed: 31059633
World Psychiatry. 2018 Oct;17(3):363-364
pubmed: 30192089
Lancet Psychiatry. 2019 Sep;6(9):778-785
pubmed: 31296444
World Psychiatry. 2018 Oct;17(3):282-293
pubmed: 30229571
World Psychiatry. 2018 Jun;17(2):187-195
pubmed: 29856559
World Psychiatry. 2018 Jun;17(2):229-230
pubmed: 29856541
World Psychiatry. 2017 Jun;16(2):142-144
pubmed: 28498590
Schizophr Res. 2019 Jun;208:235-241
pubmed: 30799218
World Psychiatry. 2017 Feb;16(1):104-105
pubmed: 28127912
World Psychiatry. 2019 Oct;18(3):357-358
pubmed: 31496107
Am Psychol. 2016 Jan;71(1):3-16
pubmed: 26766762
World Psychiatry. 2019 Oct;18(3):371-372
pubmed: 31496092
World Psychiatry. 2018 Oct;17(3):258-275
pubmed: 30192110
Am J Psychiatry. 2003 Jan;160(1):4-12
pubmed: 12505793
Riv Psichiatr. 2019 May-Jun;54(3):109-114
pubmed: 31282490
World Psychiatry. 2019 Feb;18(1):3-19
pubmed: 30600616
World Psychiatry. 2018 Jun;17(2):174-186
pubmed: 29856568
Int Rev Psychiatry. 2012 Dec;24(6):578-90
pubmed: 23244613
World Psychiatry. 2017 Oct;16(3):318-319
pubmed: 28941112
Schizophr Res. 2018 Dec;202:254-259
pubmed: 30017460
Prev Med. 2013 Dec;57(6):748-52
pubmed: 23123862
Psychol Assess. 2009 Sep;21(3):302-12
pubmed: 19719343
Int Rev Psychiatry. 2014 Aug;26(4):530-4
pubmed: 25137121
CNS Neurol Disord Drug Targets. 2017;16(8):870-884
pubmed: 28782490
World Psychiatry. 2018 Jun;17(2):239-240
pubmed: 29856538
World Psychiatry. 2018 Feb;17(1):119-120
pubmed: 29352549
J Affect Disord. 2016 Jan 1;189:314-20
pubmed: 26458184
World Psychiatry. 2018 Oct;17(3):364-365
pubmed: 30229568